The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...